Farmak’s specialists have developed L’esfal hepatoprotective drug of broad use spectrum and introduced it to the market. A new product is released in form of solution for injections.
L’esfal contains essential phospholipids (1 ml solution contains phosphatidylcholine out of soybeans 50 mg), needed to recover the structure and functions of the liver cells.
Kateryna Myrgorodska, Farmak’s Product Manager of OTC Drugs Marketing Department: “L’esfal is prescribed for the treatment of acute and chronic hepatitis, cirrhosis, fat and alcoholic liver disease, toxicosis in pregnant women and dermatological diseases.
The drug not only protects the liver from different destructive effects but recovers its affected structure. It should be noted that L’esfal may be prescribed for the children aged 12 years and older and pregnant and breast-feeding women”.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...